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Nod2 and Nod2-regulated 
microbiota protect BALB/c mice 
from diet-induced obesity and 
metabolic dysfunction
Ivan Rodriguez-Nunez, Tiffany Caluag, Kori Kirby, Charles N. Rudick, Roman Dziarski & Dipika 
Gupta
Genetics plays a central role in susceptibility to obesity and metabolic diseases. BALB/c mice are known 
to be resistant to high fat diet (HFD)-induced obesity, however the genetic cause remains unknown. 
We report that deletion of the innate immunity antibacterial gene Nod2 abolishes this resistance, as 
Nod2−/− BALB/c mice developed HFD-dependent obesity and hallmark features of metabolic syndrome. 
Nod2−/− HFD mice developed hyperlipidemia, hyperglycemia, glucose intolerance, increased adiposity, 
and steatosis, with large lipid droplets in their hepatocytes. These changes were accompanied by 
increased expression of immune genes in adipose tissue and differential expression of genes for lipid 
metabolism, signaling, stress, transport, cell cycle, and development in both adipose tissue and liver. 
Nod2−/− HFD mice exhibited changes in the composition of the gut microbiota and long-term treatment 
with antibiotics abolished diet-dependent weight gain in Nod2−/− mice, but not in wild type mice. 
Furthermore, microbiota from Nod2−/− HFD mice transferred sensitivity to weight gain, steatosis, 
and hyperglycemia to wild type germ free mice. In summary, we have identified a novel role for Nod2 
in obesity and demonstrate that Nod2 and Nod2-regulated microbiota protect BALB/c mice from diet-
induced obesity and metabolic dysfunction.
The increasing prevalence of obesity is a major health concern worldwide1. Obesity is a risk factor for other dis-
eases and more than half of all obese individuals develop metabolic abnormalities, which include hyperglycemia, 
hyperlipidemia, hepatic steatosis, and/or hypertension. Though the primary cause of obesity is an excess of caloric 
intake over expenditure, genetics and the environment play a central role in regulating metabolism and in the 
development of these diseases. In addition, the gut microbiota contributes to energy homeostasis in the host and 
changes in the composition of the gut microbiota can contribute to the development of obesity and metabolic 
disease2, 3. In turn, host genetics and environmental factors shape the microbiota and changes in either factor can 
alter intestinal bacterial populations. However, the genetic and environmental regulation of the microbiota is 
poorly understood and the specific changes in the gut bacteria that contribute to the development of obesity and 
metabolic disease are not identified.
Mouse genotype, similar to humans, greatly influences metabolism and different strains of mice differ in their 
response to high fat diet and sensitivity to metabolic diseases. BALB/c mice are naturally resistant to the devel-
opment of high fat diet (HFD)-induced obesity, however the mechanism behind this resistance is not known4. 
There is increasing evidence for the role of innate immunity in the development of metabolic disease5, 6 and in 
this study we investigated the role of the pattern recognition receptor Nod2 in the resistance of BALB/c mice to 
HFD-induced obesity.
Nod2 is involved in innate immunity to bacteria and is expressed in pro-inflammatory and antigen presenting 
cells, such as monocytes and dendritic cells, and also in structural cells, such as hepatocytes, preadipocytes, and 
intestinal epithelial cells7–10. Nod2 is a cytoplasmic sensor for bacterial peptidoglycan fragments, and stimula-
tion of Nod2 results in the activation of NF-κB and MAP kinase-signaling cascades and production of inflam-
matory molecules and anti-microbial peptides11–13. Nod2 promotes a healthy microbiota in the intestine, and 
Nod2-deficient mice have an altered gut microbiota, which promotes colitis14, 15. Nod2 was the first susceptibility 
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gene identified for Crohn’s disease16–18, however, the functional role of Nod2 in the pathogenesis of intestinal 
inflammation remains unknown and the role of Nod2 in other inflammatory and non-inflammatory disorders is 
mostly unexplored19–22.
We demonstrate in this study that deletion of the pattern recognition receptor Nod2 abolishes the resistance of 
BALB/c to HFD-induced obesity. Nod2−/− BALB/c mice on HFD gain substantially more weight than wild type 
(WT) BALB/c mice on HFD and become obese. Obese Nod2−/− BALB/c mice develop metabolic dysfunction 
including hyperlipidemia, hyperglycemia, and steatosis, and have increased adipose tissue mass and large lipid 
droplets in hepatocytes. Nod2−/− mice on HFD have dysbiosis and the altered gut microbiota contributes to the 
development of diet-dependent obesity and metabolic dysfunction.
Results
Nod2 protects from diet-induced obesity in BALB/c mice. WT and Nod2−/− female mice on BALB/c 
background, matched for weight (average 18 g) and age (6–7 weeks old) at the beginning of the experiment were 
maintained on HFD (fat 60 kcal%) or low fat diet (LFD, fat 10 kcal%) for 30 weeks. The total calories/g of food 
was the same for both diets. We observed a dramatic increase in weight gained by Nod2−/− mice compared with 
WT mice on HFD (Fig. 1a). Nod2−/− mice gained significantly more weight than WT mice starting from week 2 
on HFD, and at week 30 Nod2−/− mice gained almost twice as much weight as WT mice. As expected, WT and 
Nod2−/− mice on HFD gained significantly more weight than WT and Nod2−/− mice on LFD. There was no dif-
ference in weight gained between WT and Nod2−/− mice on LFD. Our data with WT mice concur with previous 
data showing that WT BALB/c mice do not become obese on HFD4.
Nod2−/− mice on HFD were visibly larger with substantially more fat deposits than WT HFD mice (Fig. 1b) 
and had significantly increased subcutaneous and visceral adipose tissue and an enlarged and fatty liver com-
pared with WT HFD mice (Fig. 1c and d). There was no difference in the amount of food consumed or water 
intake between WT and Nod2−/− HFD mice; average food consumed/mouse/day was 2.0 g for both genotypes 
and (Supplementary Fig. S1); the average water intake/mouse/day was 4.0 ml for both genotypes. There was also 
no significant difference in the average running distance/24 h between WT (9.48 km) and Nod2−/− (9.59 km) mice 
on regular chow (Supplementary Fig. S1).
Thus, our data demonstrate that in WT mice Nod2 protects from the development of HFD-induced obesity 
and that Nod2 deletion reverses the resistance to obesity observed in WT BALB/c mice. The increased weight 
gain in Nod2−/− HFD mice compared with WT HFD mice is not due to increased food consumption or due to an 
inherent lower activity.
Nod2 protects from diet-induced hyperlipidemia, hyperglycemia, and glucose intolerance 
in BALB/c mice. We next examined the effect of Nod2 and HFD on lipid and carbohydrate metabolism. 
Nod2−/− HFD mice exhibited significantly higher levels of serum cholesterol and triglycerides compared with 
WT HFD mice and compared with Nod2−/− and WT mice on LFD (Fig. 1e and f). Nod2−/− HFD mice had sig-
nificantly higher fasting glucose and impaired ability to restore blood glucose in response to a bolus of glucose 
compared with WT HFD mice (Fig. 1g and h), which indicates development of glucose intolerance. Nod2−/− HFD 
mice had significantly higher levels of serum insulin than WT HFD, Nod2−/− LFD, and WT LFD mice (Fig. 1i), 
and exhibited a mild but significantly reduced response to exogenous insulin compared with WT HFD mice 
120 min after an insulin challenge (Fig. 1j), which indicates the development of insulin resistance and suggests 
that partial compensation may be achieved by increased insulin production. Nod2−/− HFD mice had significantly 
higher serum levels of the anorexic hormone leptin than WT HFD mice, Nod2−/− LFD mice, and WT LFD mice 
(Fig. 1k). WT HFD mice had significantly higher triglycerides than Nod2−/− LFD and WT LFD mice, which indi-
cates the development of mild metabolic dysfunction in WT HFD mice. Nod2−/− LFD mice also had a smaller but 
significant increase in serum lipids, glucose, insulin, and leptin compared with WT LFD mice. Thus, our results 
demonstrate that Nod2−/− HFD mice develop hyperlipidemia, hyperglycemia, and glucose intolerance, which are 
hallmark manifestations of metabolic syndrome in humans.
To determine any differences in the total energy extracted from food between Nod2−/− HFD mice and WT 
HFD mice, we measured the total calories present in the stool samples of these mice. Our results show that total 
caloric value of Nod2−/− HFD feces was significantly lower than WT HFD feces (Fig. 1l). These results indicate 
that Nod2−/− mice on HFD extract more energy from the same amount of food than WT mice on HFD, which 
may be due to differences in the metabolism of host or gut microbiota.
Nod2 protects from diet-induced histopathology in BALB/c mice. We characterized the histopa-
thology in the liver and adipose tissue of Nod2−/− obese mice. Nod2−/− HFD mice had significantly larger hepat-
ocytes than WT mice on HFD and the majority of these cells had a foamy appearance, which indicates lipid 
accumulation (Fig. 2a). In BODIPY stained sections there was a dramatic and significant increase in the size of 
lipid droplets (LDs) in Nod2−/− mice compared with WT mice (Fig. 2b). The area for LDs ranged from 2 μm2 to 
300 μm2 with the highest percentage of LDs in the 36 to 75 μm2 range for Nod2−/− mice and 5 to 9 μm2 range for 
WT mice (Fig. 2c). Nod2−/− mice on HFD had significantly higher levels of liver cholesterol and triglycerides than 
WT HFD, Nod2−/− LFD, and WT LFD mice (Fig. 2d and e). Thus, our histological and biochemical data further 
support our results showing development of obesity in Nod2−/− HFD mice and also support our data for WT 
mice, which do not become obese and do not have a fatty liver (Fig. 1).
We next identified differences in the proteins associated with LDs between Nod2−/− and WT mice on HFD. 
We isolated proteins from LD-enriched fractions and identified them by mass spectrometry. All proteins that 
were significantly different (P ≤ 0.05 and fold change ≥1.5 or ≤0.6) between Nod2−/− and WT mice are directly 
or indirectly involved in lipid metabolism or in vesicle trafficking (Fig. 2f). Nod2−/− HFD mice compared with 
WT HFD mice had significantly higher levels of Abhd5, Agpat2, Gpam, and Gpd2 but decreased levels of Gpat4, 
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Figure 1. Nod2−/− mice on HFD become obese and develop hyperlipidemia, hyperglycemia, and glucose 
intolerance. WT and Nod2−/− mice were monitored for weight gain, increased adiposity, and assayed for 
metabolites. (a) Percent gain in body weight over week 0. (b–d) At week 30, (b) representative mice are shown 
for increase in overall size and visceral adipose tissue, (c) average increase in subcutaneous thickness and weight 
of visceral adipose tissue and liver per mouse, and (d) total visceral adipose tissue and liver from representative 
mice. (e–j) At week 30, mice were assayed for serum (e) cholesterol, (f) triglycerides, (g) glucose, (i) insulin, and 
(k) leptin, and for the development of (h) glucose tolerance and (j) insulin resistance. (l) Total caloric value in 
fecal samples. The results are (a) means ± SEM of 18–25 mice/group; (c,h,j) means ± SEM of 10–12 mice/group; 
or (e–g,i,k,l) for individual mice/group ± SEM. (h) Data for the glucose tolerance test is shown as ratio of HFD 
to LFD for each strain. *P ≤ 0.05, **P ≤ 0.001, Nod2−/− HFD versus WT HFD; #P ≤ 0.05, ##P ≤ 0.001, Nod2−/− 
HFD versus Nod2−/− LFD; ^P ≤ 0.05, ^^P ≤ 0.001, WT HFD versus WT LFD; +P ≤ 0.05, ++P ≤ 0.001, Nod2−/− 
LFD versus WT LFD. The results for food consumed and voluntary wheel activity are shown in Fig. S1.
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Figure 2. Nod2−/− mice on HFD develop steatosis and have large stressed adipocytes with increased infiltration 
of macrophages. (a,b) Liver sections from Nod2−/− and WT mice stained with (a) H&E or (b) BODIPY and 
DAPI. (c) Percent frequency distribution of the area (µm2) of ~5,000 LDs/group. (d,e) Quantification of liver 
cholesterol and triglycerides. (f) Heatmap representation of the fold increase (red) or decrease (green) in 
the abundance of proteins present in LD-enriched fraction from liver. The fold ratio for individual Nod2−/− 
HFD mice to the average of WT HFD mice were computed (lanes 1 to 5) with the average of the fold for all 
Nod2−/− HFD mice. (g) Adipose tissue H&E sections and a dying cell (→) is indicated. (h) Percent frequency 
distribution the area of ~8,000 adipocytes/group. (i) Average numbers of dying adipocytes (crowns) per 
3,000 cells in H&E stained sections. (j) Quantification of CD45+F4/80+ macrophage in adipose tissue. (k–m) 
Transcript levels for Adgre1, Cd68, and Tnfα in adipose tissue. Images are representative and results are (c,h,i) 
means ± SEM of 6 mice/group and (d,e,j–m) for individual mice with N = 5–10 mice/group. *P ≤ 0.05, 
**P ≤ 0.001, Nod2−/− HFD versus WT HFD; #P ≤ 0.05, ##P ≤ 0.001, Nod2−/− HFD versus Nod2−/− LFD; 
^P ≤ 0.05, WT HFD versus WT LFD; and +P ≤ 0.05, Nod2−/− LFD versus WT LFD.
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proteins associated with biosynthesis of glycerolipids. Tecr, a protein involved in the synthesis of very long chain 
fatty acids was increased in Nod2−/− HFD mice. Many proteins that participate in the catabolism of lipids were 
also more abundant in Nod2−/− HFD mice than in WT HFD mice, including Acaa1b, Acat1, Aldh7a1, Bdh1, 
Cyp2b9, Cyp4a14, Faah, Lipe, Lypla1, Mgll, and Pnpla3. Proteins associated with lipid storage were selectively 
up regulated or down regulated, Plin3 and Plin4 were present at higher and Faf2 and Plin1 at lower levels in 
Nod2−/− HFD mice. Several proteins involved in vesicle trafficking were decreased in the LD-enriched fraction 
of Nod2−/− HFD mice compared with WT HFD mice. However, Copb1, a protein associated with non-clathrin 
coated vesicles with a role in limiting lipid storage, was significantly higher in Nod2−/− HFD mice than WT HFD 
mice. These data indicate that the larger LDs in Nod2−/− HFD mice compared with WT HFD mice are accompa-
nied by changes in lipid metabolizing enzymes and in vesicle trafficking proteins.
Nod2−/− mice on HFD had enlarged adipocytes with significantly larger area than WT HFD mice (Fig. 2g and 
h). The area for adipocytes ranged from 31 μm2 to 16,000 μm2 with the highest percentage of cells in the 2000 to 
4000 μm2 range for Nod2−/− mice and 250 to 500 μm2 for WT mice (Fig. 2h). Nod2−/− mice had significantly more 
“crowns”, which are dead adipocytes surrounded by immune cells (Fig. 2g and i, indicated by an arrow) and are a 
characteristic feature of stressed adipose tissue associated with obesity. Nod2−/− mice on HFD had significantly 
more F4/80+ macrophages in adipose tissue than WT mice on HFD, Nod2−/− LFD, and WT LFD mice (Fig. 2j) 
with a corresponding increase in the transcripts for Adgre1 (gene for F4/80) and Cd68, another marker for mono-
cytes/macrophages (Fig. 2k and l). Expression of Tnfα, an inflammatory cytokine associated with obesity was 
enhanced (Fig. 2m). Thus, our data demonstrate that Nod2 protects from lipid accumulation in the adipose tissue 
and liver, and that development of diet-dependent obesity in Nod2−/− HFD mice is associated with steatosis, 
formation of large LDs in hepatocytes, stressed adipocytes, and infiltration of macrophages in the adipose tissue.
Diet-dependent obesity in Nod2−/− mice is associated with changes in the expression of adi-
pose tissue genes involved in immune responses and intermediary metabolism. We identified 
genes that were differentially expressed in the visceral adipose tissue of WT and Nod2−/− BALB/c mice main-
tained on HFD for 30 weeks using RNA transcriptomics. Nod2−/− HFD mice had 357 genes with significantly 
increased expression (and fold change ≥2) and 169 genes with significantly decreased expression (and fold 
change ≤0.5) compared with WT mice on HFD (Supplementary Fig. S2). 79% of the differentially expressed 
genes are associated with a function or pathway (Ensembl or DAVID) and are shown in Fig. 3 and Supplementary 
Table S1. More than 100 genes that directly or indirectly participate in immune responses were differentially reg-
ulated and the majority of these genes (>80) were significantly up regulated in the adipose tissue of Nod2−/− HFD 
mice compared with WT HFD mice. These genes code for transcription factors, signaling molecules, effector 
molecules, enzymes, and receptors, all involved in regulating immune cells and responses. For example, Nod2−/− 
mice on HFD had increased expression of genes for (i) chemokines Ccl2, Ccl5, Ccl7, Ccl8, Ccl12, Ccl22, and Cxcl1, 
which recruit monocytes, eosinophils, and lymphocytes; (ii) enzymes involved in arachidonic acid and eicosa-
noid metabolism, Cyp2c39, Cyp2d10, Cyp4f14, Fam213b, Pla2g12b, and Ptges3l; (iii) receptors involved in T cell 
activation, including Cd3δ, Cd3ε, Cd3γ, Cd4, Cd5, Cd6, and Cd52; and (iv) adipokines Sfrp5, Stra6l, and Wisp2, 
and the protease Cpn1. Expression of genes for adipsin (Cfd) and regulators of adipokines, Hcar2 and Ptprn2, was 
decreased.
The second largest group of genes that was differentially regulated between WT and Nod2−/− HFD mice 
directly or indirectly participates in intermediary metabolism, primarily lipid metabolism (Fig. 3, Supplementary 
Table S1). These genes include: (i) enzymes involved in breakdown of fatty acids and glycerolipids, for example, 
Acot3, Acot4, Ces4a, Agpat9, and Pnpla1 were increased; (ii) members of the acyl-CoA synthetase medium chain 
family were up regulated (Acsm1) or down regulated (Acsm3 and Acsm5); (iii) enzymes in the synthesis of fatty 
acids and triglycerides, Mogat2 and Scd1, were increased; (iv) transporters for fatty acids, cholesterol, glycerolip-
ids, and glycerol, Abcc2, Aqp11, Atp8b5, Fabp5, and Mfge8, were up regulated, and Apold1, Glcci1, and Slc27a1, 
were down regulated.
Nod2−/− mice on HFD had several differentially expressed genes that directly or indirectly participate in 
amino acid and carbohydrate metabolism compared with WT HFD mice (Fig. 3, Supplementary Table S1). These 
genes include: (i) enzymes in amino acid metabolism, Accsl, Agxt, and Aspg were decreased or Got1l1, Hgd, Sds, 
and Sdsl were increased and (ii) amino acid transport, Slc22a2, Slc7a14, and Uroc1 were increased. Genes for: (i) 
enzymes in carbohydrate metabolism, Gys2, Lctl, Mgam, and Ppp1r3e and (ii) glucose transport, Adamts5, Rtn2, 
Slc2a2, Smpd5, and Syp were up regulated, but (iii) insulin signaling, Dusp9, Fbxo40, Grb14, and Ptpre were down 
regulated.
Nod2−/− mice on HFD had an overall decrease in the expression of genes involved in (i) neural signaling, 
including Brinp3, Cadps2, Dlg2, Itpka, Mylka, Prickle2, Shisa6, Sorcs1, Syt15; (2) nerve adhesion, Celsr2, Cntn1, 
Fat3, Lsamp, Ncam1, Ncam2, Nfasc, and Nlgn1; and (iii) transcriptional regulators for neural development, Ascl1, 
Hesx1, and Id4 (Fig. 3, Supplementary Table S1).
Genes involved in other cellular functions, including cell cycle, development, cell adhesion, and cytoskele-
ton were also differentially expressed (Fig. 3, Supplementary Table S1). Nod2−/− HFD mice also had an over-
all decrease in the expression of genes involved in (i) cell adhesion and signaling, including Adgra1, Adgrg2, 
Cdh12, Cdh9, Cldn22, Col12a1, Col6a5, Col6a6, Pcdh20, Pcdhb12, Pcdhb16, Pcdhb18, Pcdhb9, Rassf6, Sned1, and 
Thsd4; and (ii) inhibition of apoptosis, including Angpt1, Dusp26, Egln3, Hspa1a, and Pde3a. There was an over-
all increase in expression of genes involved in: (i) DNA structure, repair and chromatin silencing, for exam-
ple, Hist1h1d, Hist1h1e, Hist1h2al, Hist1h2be, Hist2h3c2, and Mutyh; (ii) transcription and post-transcriptional 
processing, Abra, Inpp4b, Lbx2, Pcbd1, Pnldc1, Rbm28, and Rpph1; and (iii) proteases and protease inhibitors, 
Adam23, Cpa2, Itih1, Itih3, Lonrf3, Psma8, Serpina11, Serpina1d, Serpina1e, Serpina3e-ps, Serpina3m, and 
Wfdc18. However, there was a noticeable decrease in genes involved in translation and post-translational pro-
cessing, B3galt1, B3galt2, Fam129a, Galnt5, St8sia2, Tgm3, Tgm5, Ttll2, and Ttll7.
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Figure 3. Differential expression of genes for immunity, metabolism, and other cellular functions in the 
adipose tissue of Nod2−/− mice on HFD. Heatmap representation of the fold increase (red) or decrease (green) 
for gene expression in the adipose tissue of Nod2−/− HFD mice compared with WT HFD mice. The genes are 
grouped based on function or pathway. The fold ratio for individual Nod2−/− HFD mice to the average of WT 
HFD mice was computed and is shown (lanes 1 to 6) with the average of the fold for all Nod2−/− HFD mice. 
Genes that had a fold change of ≥2 or ≤0.5 (≤−2) and P ≤ 0.05 with 5% FDR are included in the heatmap. 
N = 6 mice/group. The numerical data for fold increase in individual mice, the average, P value, and FDR are 
shown in Supplementary Table S1.
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Thus, our results indicate that genes involved in a wide array of pathways and cellular functions are differen-
tially regulated in the adipose tissue of Nod2−/− HFD mice compared with WT HFD mice. These changes in gene 
expression may contribute to the increased adiposity, steatosis, obesity, and metabolic dysfunction observed in 
Nod2−/− mice on HFD. Future studies should confirm these changes at the protein level and focus on their role in 
the development of obesity in Nod2−/− HFD mice.
Diet-dependent obesity in Nod2−/− mice is associated with changes in the expression of liver 
genes involved in intermediary metabolism. We next identified genes that were differentially expressed 
in the liver of WT and Nod2−/− BALB/c mice maintained on HFD for 30 weeks using RNA transcriptomics. 
Nod2−/− HFD mice had 188 genes with significantly increased expression (and fold change ≥2) and 130 genes 
with significantly decreased expression (and fold change ≤0.5) compared with WT mice on HFD (Supplementary 
Fig. S2). 87% of the differentially expressed genes are associated with a function or pathway (Ensembl or DAVID) 
and are shown in Fig. 4 and Supplementary Table S2. Of these genes, there were more than 60 genes that directly 
or indirectly participate in intermediary metabolism, primarily lipid metabolism and include genes for enzymes, 
transport, and regulation. For example, Nod2−/− HFD mice had higher expression of enzymes and regulators 
involved in: (i) synthesis and storage of fatty acids, triglycerides, steroids, and glycolipids, Acacb, Acss2, Elovl3, 
Elovl6, Fitm1, G0s2, Hsd3b5, Mogat1, Scd1, and St6galnac4; (ii) catabolism of lipids, Pla2g4f, Pnpla3, Pnpla5, 
Pex11a, and Phyhip; and (iii) carbohydrate metabolism, Gck, Pdk4, and Ppp1r3e. Several genes involved in trans-
port of metabolites and nutrients were down regulated, including Aqp4, Fabp5, Ndgr1, and Slco1A1, whereas 
other transporters were up regulated, including Cd36, Mfsd2a, Osbpl5, Pltp, Slc10a2, Slc16a13, and Slc2a4 (Glut4). 
Nod2−/− HFD mice had decreased expression of the leptin receptor (Lepr).
Nod2−/− mice on HFD had about 50 genes involved in immune responses that were differentially expressed 
in the liver compared with WT mice on HFD (Fig. 4, Supplementary Table S2). Transcription factors involved in 
the activation of immune cells, Arl2bp, Cbfa2t3, and Cebpε, were increased, whereas transcriptional repressors 
Bcl6 and Cam1kd were decreased. There was a noticeable increase in the expression of many interferon-induced 
genes, including the chemokines Cxcl9, Cxcl10, and Cxcl11. Genes for the T cell receptor Cd8α and retinoic acid 
metabolism, Cyp26b1, Raet1δ, and Raet1ε, that regulate T and NK cell immune responses were induced, but genes 
in arachidonic acid metabolism, Alox15, Cyp2c54, Cyp2g1, and Cyp2s1, were inhibited.
Nod2−/− mice on HFD had increased expression of many liver genes involved in DNA structure, replication, 
and repair (Fig. 4, Supplementary Table S2). Genes for serine protease inhibitors (Itih5, Serpina4-ps1, Serpina7, 
and Serpina9), chaperones (Hsp1a and Hsp1b), and ubiquitination (Kelch33, Klhl33, Trim13, and Ube2ql1) were 
decreased. Genes for cell cycle and cell proliferation were overwhelmingly induced, however many genes involved 
in development were down regulated, including transcription factors (Irx1, Klf4, Meox1, Sox9, Sp5, and Tbx3), 
signaling molecules (Arhgef40, Dact2, Mpzl1, Mrgpre, and Pdgfc) and components of the Wnt pathway (Axin2, 
Bcl7c, Wif1, and Lgr5). Several genes involved in neural development were down regulated, including proteins 
involved in ion and vesicular transport (Adam11, Cacnα1d, Syngr1, and Syt9) and neural signaling (Aph1c, 
Cadm4, and Pde6c). However, genes for acetylcholine receptor (Chrna4) and signaling at the neuronal junction 
were up regulated (Clstn3, Cntnap1, and Pclo). The tyrosine kinase receptor, Ntrk2, which has a role in suppress-
ing appetite, was also up regulated (Fig. 4, Supplementary Table S2).
Nod2−/− mice on HFD had increased expression of many genes involved in extracellular matrix organization 
and cell adhesion, including Col27a1, Esm1, Hapln1, Hmcn2, Lamb3, Myo7b, and Pcdh17. Genes involved in ves-
icle trafficking (Rab11fip4, Rab2b, Rasl2–9, and Sptb) and proton, sodium and sulfur transport (Atp6v0d2, Slc4a9, 
Slc8a3, Sult3a1, Sult5a1, and Wnk4) were down regulated, whereas genes for zinc and iron uptake (Slc39a5 and 
Tfrc) were increased (Fig. 4, Supplementary Table S2).
These results indicate that in the liver, genes involved in a wide array of pathways and cellular functions are 
differentially regulated by HFD in Nod2−/− mice compared with WT mice. These changes in gene expression may 
contribute to the increased adiposity, steatosis, obesity, and metabolic dysfunction observed in Nod2−/− mice on 
HFD. Future studies should confirm these changes at the protein level and focus on their role in the development 
of obesity in Nod2−/− HFD mice.
Nod2−/− genotype and HFD and LFD affect diversity of stool microbiome. Because intestinal 
microbiome is important for energy extraction from food, we determined the diversity of intestinal bacteria in 
WT and Nod2−/− mice on HFD and LFD, to identify in detail the differences in their intestinal microbiota. We 
isolated DNA from stool microbiota and performed genetic phylotyping (community profiling) using pyrose-
quencing of the variable regions of bacterial 16S ribosomal RNA (rRNA) genes. To determine the effect of geno-
type, we compared microbiomes in WT and Nod2−/− mice on the same diets, and to determine the effect of diets, 
we compared microbiomes in mice of the same genotype fed HFD or LFD.
We first evaluated α-diversity of the microbiomes of WT and Nod2−/− mice on HFD and LFD. We identified 
a total of 223 species and 4425 operational taxonomic units (OTUs) in the stools of all mice: 153, 172, 180, and 
164 species and 2344, 2589, 2392, and 2381 OTUs in WT HFD, Nod2−/− HFD, WT LFD, and Nod2−/− LFD mice, 
respectively. The total number of OTUs identified in Nod2−/− HFD mice was significantly higher than in WT HFD 
mice, whereas the total numbers of OTUs in Nod2−/− LFD and WT LFD mice, as well as total numbers of species 
in all groups of mice were similar with no significant differences between the groups (Supplementary Fig. S3). The 
numbers of species and OTUs per mouse (microbiome richness) were similar in all groups of mice, except for WT 
LFD mice, which had significantly more species/mouse than WT HFD mice. Both Shannon diversity indices (H) 
and Shannon equitability indices (EH, reflecting microbiome evenness) were significantly higher for the species 
in Nod2−/− HFD than in WT HFD mice, and for both the species and OTUs in WT LFD than in Nod2−/− LFD 
mice, and also for both the species and OTUs in WT LFD than in WT HFD mice (Supplementary Fig. S3). These 
www.nature.com/scientificreports/
8Scientific RepoRts | 7: 548  | DOI:10.1038/s41598-017-00484-2
Figure 4. Differential expression of genes for immunity, metabolism, and other cellular functions in the liver 
of Nod2−/− mice on HFD. Heatmap representation of the fold increase (red) or decrease (green) for gene 
expression in the adipose tissue of Nod2−/− HFD mice compared with WT HFD mice. The genes are grouped 
based on function or pathway. The fold ratio for individual Nod2−/− HFD mice to the average of WT HFD mice 
was computed and is shown (lanes 1 to 6) with the average of the fold for all Nod2−/− HFD mice. Genes that 
had a fold change of ≥2 or ≤0.5 (≤−2) and P ≤ 0.05 with 5% FDR are included in the heatmap. N = 6 mice/
group. The numerical data for fold increase in individual mice, the average, P value, and FDR are shown in 
Supplementary Table S2.
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results show that both Nod2−/− genotype on HFD and WT genotype on LFD may increase α-diversity, although 
these changes are very modest.
We then evaluated β-diversity of the microbiomes. Microbiota from stools of all four groups of mice (WT 
HFD, Nod2−/− HFD, WT LFD and Nod2−/− LFD) separated from each other in the Principal Coordinate Analysis 
(PCoA), with microbiota from each group of mice showing distinct and significant separation from the microbi-
ota of all other groups of mice (Fig. 5a). These results suggested differences in β-diversity in the intestinal micro-
biomes between all four groups of mice with both the genotype (WT and Nod2−/−) and the diet (HFD and LFD) 
affecting β-diversity of stool microbiomes. These results prompted us to further identify the differences between 
these microbiomes.
We detected many statistically significant effects of both Nod2 genotype and the diet on bacterial β-diversity, 
with many significant changes in the abundance of various bacterial groups in the stools at all taxonomic levels. 
For example, at the class level (Fig. 5b and Supplementary Fig. S4), WT HFD mice had significantly increased 
abundance of Epsilonproteobacteria compared with Nod2−/− HFD mice, and Nod2−/− HFD mice had significantly 
increased abundance of Deferribacteres compared with WT HFD mice. In mice on LFD, WT mice had signifi-
cantly higher abundance of Candidatus saccharibacteria than Nod2−/− mice, and Nod2−/− mice had significantly 
higher abundance of Deferribacteres than WT mice. The diet also had a pronounced effect on stool microbiota. 
HFD significantly increased the abundance of Clostridia and Deltaproteobacteria in both WT and Nod2−/− mice 
and also Deferribacteres in Nod2−/− mice, whereas LFD significantly increased the abundance of Bacteroida, 
Bacilli, and Erysipelotrichia in both WT and Nod2−/− mice, and also Candidatus saccharibacteria in WT mice.
At other taxonomic levels, significant differences in abundance in the following numbers of orders, families, 
genera, species, and OTUs (out of total of 27, 47, 109, 223, and 4425) were detected: between WT HFD and 
Nod2−/− HFD mice, 2, 2, 9, 26, and 548; between WT LFD and Nod2−/− LFD mice, 6, 10, 20, 46, and 601; between 
WT HFD and WT LFD, 8, 14, 24, 48, and 535; and between Nod2−/− HFD and Nod2−/− LFD mice, 6, 9, 16, 35, 
and 288, respectively (NCBI SRA, accession No. SRP076031). Thus, both Nod2 genotype of mice and their diet 
together significantly influence the diversity of their microbiomes.
We then further analyzed the differences in microbiomes between Nod2−/− HFD mice and the remain-
ing groups of mice, because these mice had significantly higher weight gain and significant manifestations of 
metabolic syndrome compared with the other groups of mice, and moreover, these differences were abolished 
by treatment with antibiotics (next section). Nod2−/− HFD mice, compared with WT HFD mice, had signif-
icantly higher abundance of six Firmicutes, three Bacteroidetes, two Deferribacteres, one Proteobacteria, and 
one Actinobacteria species (Table 1). Importantly, three of these bacterial species, both Deferribacteres and one 
Firmicutes (Lachnoclostridium phytofermentans) had significantly higher abundance in Nod2−/− HFD mice than 
in the other three groups of mice, thus showing the best correlation with obesity and metabolic syndrome, since 
Nod2−/− HFD mice was the only group with significantly higher obesity and metabolic syndrome. There were no 
bacterial species with significantly decreased abundance in Nod2−/− HFD mice compared with all other groups 
of mice.
Diet-induced obesity in Nod2−/− BALB/c mice is abolished by long-term antibiotic treat-
ment. We next determined the role of the gut microbiota in diet-dependent obesity in Nod2−/− mice by 
depleting gut bacteria with antibiotics. WT and Nod2−/− mice, starting at 4 weeks of age, were given an antibiotic 
mix (Abx) of ciprofloxacin and metronidazole in their drinking water, which is an established method for deplet-
ing gut bacteria20, 23–25. After three weeks the animals were placed on HFD and Abx were continued, and body 
weight was measured each week (Fig. 6a). Control mice were started on HFD at the same age, but never treated 
with Abx. Our results demonstrate that Abx treatment completely abolished the diet-dependent weight gain in 
Nod2−/− mice, but did not affect the weight gain in WT mice (Fig. 6b). Nod2−/− Abx HFD mice gained signifi-
cantly less weight than Nod2−/− HFD mice, and also less than WT HFD mice with and without Abx. There was 
no difference in weight gained between WT Abx HFD and WT HFD mice. There was no difference in food con-
sumption or water intake between the WT Abx HFD and Nod2−/− Abx HFD, as average food consumed/mouse/
day was 1.86 g and 1.89 g, respectively, and the average water intake/mouse/day was 2.9 ml for both genotypes. 
There is some decrease in water intake between the antibiotic treated versus control mice, however this decrease 
does not account for the difference in the weight gain observed between WT and Nod2−/− mice, because both 
genotypes on antibiotics had similar decrease in water intake but only Nod2−/− mice had significantly reduced 
weight gain.
We next determined whether the antibiotic-induced loss in weight gain was accompanied by decreased lipid 
accumulation in the liver of Nod2−/− mice using histological and biochemical assays. Our results demonstrate that 
Nod2−/− mice treated with long-term Abx and maintained on HFD had smaller LDs in hepatocytes compared 
with Nod2−/− mice not treated with Abx but maintained on HFD (Fig. 6c). The area for LDs ranged from 2 μm2 
to 300 μm2 with the highest percentage of LDs in the 36 to 75 μm2 range for the HFD mice and 2 to 19 μm2 range 
for Abx + HFD mice (Fig. 6d). Nod2−/− mice on Abx + HFD had significantly lower levels of liver cholesterol and 
triglycerides than control Nod2−/− mice on HFD alone (Fig. 6e and f). Furthermore, Nod2−/− mice on Abx + HFD 
had significantly lower levels of serum cholesterol and triglycerides (Fig. 6g and h), but no significant difference 
in glucose, compared with control Nod2−/− mice on HFD alone.
Thus, our results demonstrate that the gut microbiota in Nod2−/− HFD mice is required for the development 
of diet-dependent obesity, steatosis, and hyperlipidemia in Nod2−/− mice, and that long-term treatment with 
broad-spectrum antibiotics abolishes weight gain and several aspects of metabolic dysfunction.
Intestinal microbiota from Nod2−/− mice on high fat diet increases sensitivity to obesity. We 
next considered whether the altered gut microbiota in Nod2−/− mice on HFD is sufficient for the development 
of diet dependent obesity. We colonized germ-free pregnant female WT Swiss-Webster mice by co-housing with 
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either Nod2−/− HFD mice or WT HFD mice, and also by weekly gavaging with microbiota from either Nod2−/− 
HFD mice or WT HFD mice. We placed these mice on HFD after the first gavage (Fig. 7a). We removed the 
co-housed mice one day after delivery, but continued weekly gavaging and HFD, and monitored the weight gain 
Figure 5. β-diversity in stool microbiota of WT HFD, Nod2−/− HFD, WT LFD, and Nod2−/− LFD mice. (a) 
Principal Coordinate Analysis (PCoA) by UniFrac (unweighted) of microbiomes. Each sphere with confidence 
elipsoid corresponds to a stool microbiome from one mouse. N = 6 mice/group. (b) Class abundance expressed 
as % of total stool microbiota; *classes with significantly (at P ≤ 0.05) increased abundance in WT versus 
Nod2−/− mice (on HFD or LFD); #classes with significantly (at P ≤ 0.05) increased abundance in HFD versus 
LFD groups (for WT or Nod2−/− mice); N = 6 mice/group. The results for individual mice are shown in 
Supplementary Fig. S4. The entire microbiome analysis data comparing bacterial diversity in the stools of WT 
and Nod2−/− mice maintained on HFD and LFD have been deposited in NCBI SRA, accession No. SRP076031.
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of pups for 8 weeks. Germ-free pups colonized with microbiota from Nod2−/− HFD mice were more susceptible 
to HFD-dependent weight gain than pups colonized with microbiota from WT HFD mice, as manifested by 
significantly higher weight gain (Fig. 7b). Furthermore, pups colonized with Nod2−/− HFD microbiota were also 
more susceptible to HFD-induced metabolic dysfunction, as they had significantly higher liver cholesterol and 
triglycerides, and higher serum glucose than pups colonized with microbiota from WT HFD mice (Fig. 7c–e), 
but there was no difference in serum cholesterol or triglycerides between the 2 groups of mice. In conclusion, 
microbiota from Nod2−/− HFD mice can transfer to WT outbred germ-free mice enhanced susceptibility to 
HFD-dependent weight gain and metabolic dysfunction.
Discussion
Multiple factors, including host genetics, microbiota, and the environment regulate sensitivity to obesity and met-
abolic disease and development of their clinical manifestations. However, the specific components that promote 
or protect from these diseases are poorly understood. There is increasing evidence for cross talk between innate 
immunity and metabolism and for their combined role in the development of obesity and associated diseases6, 26–28. 
However there is no previous evidence for the role of the innate immunity gene Nod2 in regulating sensitiv-
ity to obesity. Here we have discovered that Nod2 and Nod2-dependent microbiota protect BALB/c mice from 
HFD-induced pathology.
We show that Nod2−/− BALB/c mice on HFD become obese and exhibit many key manifestations of metabolic 
disease including hypercholesterolemia, hypertriglyceridemia, hyperglycemia, and hyperinsulinemia, increased 
adiposity, and steatosis. The effect of Nod2 deletion on HFD-induced obesity is strain-dependent, as Nod2−/− and 
WT C57BL/6 mice on HFD gain similar weight, but Nod2−/− C57BL/6 mice exhibit more severe insulin resist-
ance21 than Nod2−/− BALB/c mice. Thus, Nod2 differentially regulates the response of BALB/c and C57BL/6 mice 
to HFD, which emphasizes the importance of the host’s entire genetic background in regulation of obesity and 
metabolic syndrome and reflects the variability in the development of disease in humans.
Metabolic inflammation plays a key role in the development of obesity and metabolic diseases in humans 
and in animal models of obesity5, 6. Our results also demonstrate that HFD-dependent obesity in Nod2−/− mice 
correlates with increased expression of a large number of genes in adipose tissue that participate in immune 
responses. They include genes for chemokines and cell surface molecules involved in the recruitment and activa-
tion of T cells, monocytes, dendritic cells and eosinophils, and for enzymes in eicosanoid metabolism. In addi-
tion, Nod2−/− HFD mice have increased infiltration of F4/80+ macrophages and enhanced levels of the transcripts 
of Adgre1 (gene for F4/80) and CD68, also a marker for monocytes/macrophages29, in the adipose tissue. Similar 
to our results, increased inflammatory markers were also observed in Nod2−/− C57BL/6 mice on HFD21, which 
suggests that inflammation likely plays an important role in the development of metabolic dysfunction in both 
strains of mice.
Development of obesity is usually accompanied by dysfunction in lipid and/or carbohydrate metabolism, 
and our results also demonstrate that HFD-dependent obesity in Nod2−/− mice correlates with changes in the 
expression of many genes involved in intermediary metabolism, primarily lipid metabolism. Several of these 
differentially expressed genes and their products have an established role in the development of obesity or are 
associated with metabolic diseases30–35. Leptin is an adipokine that regulates appetite and energy balance, and in 
obese individuals there is decreased sensitivity to leptin, which may result in increased appetite36. Nod2−/− mice 
on HFD have elevated levels of serum leptin, enhanced transcription of leptin (Lep) in the adipose tissue, and 
decreased expression of the leptin receptor in the liver (Lepr). These results suggest that Nod2−/− mice on HFD 
develop resistance to leptin, however there was no difference in the amount of food consumed between WT 
and Nod2−/− mice on HFD. Genes known to participate in multiple other biological pathways, including DNA 
Phylum Species
Nod2−/− HFD (% 
abundance)
WT HFD (% 
abundance)
Firmicutes
Hydrogenoanaerobacterium sp. 0.76 0.52
Coprococcus eutactus 0.34 0.052
Eubacterium rectale 0.18 0.049
Lachnoclostridium (Clostridium) 
phytofermentans 0.15 0.0000
Coprococcus catus 0.076 0.0000
Blautia (Ruminococcus) obeum 0.027 0.0025
Bacteroidetes
Rikenella sp. 4.49 1.49
Bacteroides sp. 1.58 0.71
Butyricimonas sp. 0.011 0.0000
Deferribacteres
Mucispirillum sp. 2.27 0.0000
Mucispirillum (Flexistipes) sp. 0.30 0.0000
Proteobacteria Helicobacter ganmani 0.058 0.0000
Actinobacteria Adlercreutzia equolifaciens 0.028 0.0025
Table 1. Bacterial species with significantly higher abundance in Nod2−/− HFD mice than in WT HFD mice*. 
*P < 0.05 for all species. The entire microbiome analysis data comparing bacterial diversity in the stools of WT 
and Nod2−/− mice maintained on HFD and LFD have been deposited in NCBI SRA, accession No. SRP076031.
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Figure 6. Antibiotic treatment prevents the development of obesity, steatosis, and metabolic dysfunction in 
Nod2−/− mice on HFD. (a) Nod2−/− and WT mice were treated with Abx to deplete their intestinal microbiota. 
Control mice were not treated with antibiotics. Three weeks after the start of Abx all mice were placed on HFD 
and monitored for weight gain, histopathology, and metabolites. (b) Percent gain in weight compared to week 0 
of HFD. (c,d) After 14 weeks of HFD, mice were analyzed for liver histopathology in BODIPY and DAPI stained 
sections and (d) percent frequency distribution of LD area (µm2) for ~4,000 LDs/group. (e–h) After 14 weeks 
of HFD, (e) liver triglycerides, (f) liver cholesterol, (g) serum cholesterol, and (h) serum triglycerides were 
measured. (b,d) Results are means ± SEM, (C) representative images, and (e–h) individual data of 6–10 mice/
group. *P ≤ 0.05 and **P ≤ 0.001, Nod2−/− Abx + HFD versus Nod2−/− HFD.
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structure, gene expression, cell cycle, development, neural processes, transport, cytoskeleton, and extracellular 
matrix were also differentially expressed between Nod2−/− HFD mice compared with WT HFD mice, which sug-
gest the development of a complex pathology.
Obesity is often associated with non-alcoholic fatty liver disease, and Nod2−/− mice on HFD also exhibit 
similar manifestations, including enlarged fatty liver, elevated levels of cholesterol and triglycerides in the liver, 
and large LDs in the hepatocytes. LDs are composed of a lipid core surrounded by a phospholipid monolayer and 
are coated with proteins that regulate LD physiology, including enzymes in lipid metabolism and members of 
the perilipin family, which regulate lipid metabolism and trafficking37, 38. The development of LDs is regulated by 
multiple factors, including host genetics, composition of the intestinal microbiota, and diet37–40. Using proteomics 
we identified many proteins in the LD enriched fraction with significantly changed abundance in Nod2−/− HFD 
mice compared with WT HFD mice. All identified proteins have known functions in lipid metabolism and/or 
vesicle trafficking and several of these proteins, for example Abhd5, Pnpla3, and COPI, have an established role or 
are associated with obesity and /or steatosis37, 38, 41–45. In addition, many genes involved in lipid synthesis, degra-
dation, and storage were differentially regulated in the liver of Nod2−/− mice on HFD compared with WT mice on 
HFD. These results, thus, provide clues for the molecular mechanism responsible for the development of steatosis 
in Nod2−/− HFD mice. Moreover, the altered microbiota in Nod2−/− HFD mice also contributes to increased lipid 
accumulation in hepatocytes and may play a role in the formation of large LDs.
Obese mice and humans often show increased abundance of Firmicutes and Proteobacteria, but decreased 
abundance of Bacteroidetes3, 46, 47. Accordingly, our results also show higher abundance of six Firmicutes species 
and one Proteobacteria species in obese Nod2−/− HFD mice compared with non-obese WT HFD mice. The abun-
dance of several of these species is also increased in obese humans48–51. Our results comparing the abundance 
of Bacteroidetes in obese and non-obese mice were mixed: three Bacteroidetes species were increased and two 
were decreased in Nod2−/− HFD mice compared with WT HFD mice, consistent with many exceptions to the 
general rule of decreased Bacteroidetes in obesity, e.g., increased abundance of Bacteroides was found in some 
obese and obese-prone populations52, 53. Also, consistent with the association of inflammation with obesity, the 
abundance of two members of Deferribacteres were increased in obese Nod2−/− HFD mice compared with all 
other non-obese groups of mice, as Deferribacteres are early markers of inflammation54. Our results concur with 
previous data showing dysbiosis in Nod2−/− C57BL/6 mice on HFD21, but the specific differences were not the 
same as those seen in Nod2−/− BALB/c mice on HFD.
Figure 7. Intestinal microbiota from Nod2−/− mice on HFD increases susceptibility of germ-free mice to 
HFD-induced obesity and metabolic dysfunction. (a) One week before delivery, we colonized germ-free WT 
Swiss Webster female pregnant mice, kept under sterile conditions, with microbiota from WT or Nod2−/− 
mice maintained on HFD. Colonization was done by both gavaging with fecal microbiota and by co-housing. 
Gavaging was done into the stomach with fecal homogenates from WT or Nod2−/− mice maintained on HFD 
(indicated by ↑). At the same time, the gavaged mice were placed on HFD and also co-housed with Nod2−/− or 
WT female mice that had been maintained on HFD for ~20 weeks. The co-housed Nod2−/− HFD and WT 
HFD mice were removed when the pups were born (week 0). Mothers and pups were maintained on HFD for 
the length of the experiment. (b–e) Pups were monitored for (b) gain in weight every week and after 8 weeks 
assayed for (c) liver cholesterol, (d) liver triglycerides and (e) serum glucose. (b) Results are means ± SEM and 
(c–e) individual data of 19–21 mice/group. *P ≤ 0.05 and **P ≤ 0.001, Nod2−/− Abx + HFD versus Nod2−/− 
HFD.
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There is increasing evidence indicating a role for the gut microbiota in the development of obesity in humans 
and in animal models of obesity2, 3. Microbiota with increased capacity for harvesting energy, referred to as “obese 
microbiota”, has been identified in obese individuals, and furthermore, the obese microbiota from humans can 
transfer the obesity phenotype to mice55, 56. Our results showing abrogation of obesity and metabolic changes in 
Nod2−/− HFD mice by antibiotics and transfer of increased sensitivity to obesity in germ-free mice by microbi-
ota from Nod2−/− HFD mice suggest that Nod2 may protect mice from harboring such “obese microbiota”. This 
notion is further supported by a decreased total energy content in the stools of Nod2−/− HFD mice compared 
with WT HFD mice, suggesting greater extraction of energy from food in Nod2−/− HFD mice, leading to obesity 
and metabolic disease. These results indicate that there are many similarities in the mechanisms responsible for 
microbiota-induced obesity in humans and mice, although the specific bacteria present in humans and mice may 
differ.
In summary, we have discovered that deletion of Nod2 abolishes the resistance of BALB/c mice to 
HFD-induced obesity and metabolic dysfunction. The development of obesity and metabolic dysfunction in 
Nod2−/− mice on HFD has many similarities to the development of HFD-induced pathology in humans, which 
makes Nod2−/− BALB/c mice a relevant model for the study of HFD-induced obesity and associated diseases.
Methods
Mice. Nod2−/− mice on BALB/c background were described previously and deletion of the Nod2 genes was 
confirmed by PCR analysis of genomic DNA19, 20. The original founder WT BALB/c mice were obtained from 
Harlan-Sprague-Dawly. WT germ-free mice (Swiss Webster female and male) were obtained from Taconic Farms 
(Hudson, NY). All WT and Nod2−/− mice on BALB/c background were bred and kept under conventional path-
ogen-free conditions in the same room in our facility to minimize the influence of differences in the environ-
ment. For each experiment, mice from several different cages and breeder pairs were used. To avoid changes in 
microbiome that could accumulate over extended period of time, we backcross our mutant mice to WT females 
once every other year and re-derive our homozygous knockout breeding pairs. The latter strategy also minimized 
genetic drift in the population. Some investigators use knockout and WT littermates from heterozygous breeding 
pairs to minimize parent-to-parent and cage-to-cage variations. We do not use this strategy for two reasons: first, 
this strategy may skew the results to the particular microbiota present only in this breeding pair. Second and 
most importantly, we noticed that the effect of innate immunity genes on the composition of microbiota is not 
instantaneous, but takes time, and stabilization of microbiota characteristic of a given knockout may take more 
than one generation20. The BALB/c background of knockout mice and their negative status for all common viral 
and bacterial pathogens and parasites were confirmed as previously described19. The Indiana University School 
of Medicine-Northwest Institutional Animal Care and Use Committee approved all experiments with mice. All 
methods were performed in accordance with the relevant guidelines and regulations.
Obesity model in conventional mice. WT and Nod2−/− female mice in BALB/c background, matched 
for weight and age (6–7 weeks old) were randomly divided into two groups and started on HFD (fat 60 kcal%, 
D12492) or LFD (fat 10 kcal%, D12450B) from Research Diets and maintained on the special diets until the end 
of the experiment (14 or 30 weeks). The total calories/g of HFD and LFD were the same. Mice were weighed 
every week and the amount of food consumed each week was measured to confirm that the differences in obe-
sity are not due to differences in food intake. One to two weeks before sacrifice, stool samples were collected for 
microbiota analysis, bomb calorimetry and for microbiota transplant experiments, fasting glucose was assayed, 
and glucose tolerance and insulin resistance assays performed. At the time of sacrifice, blood was collected for 
biochemical assays; visceral adipose tissue and liver were weighed and subcutaneous adipose tissue was measured 
with a micrometer. Visceral adipose tissue and liver were processed for histology, RNA, and flow cytometry. Lipid 
droplets were purified from the liver and proteins identified by mass spectrometry. We focused on adipose tissue 
and liver, because they are the major organs involved in intermediary metabolism.
Obesity in antibiotic-treated mice. We depleted the microbiota in WT and Nod2−/− mice using an estab-
lished antibiotic treatment20, 23–25. Mice were matched for weight and age and randomly divided into two groups. 
One group of 4 weeks old mice was started on an antibiotic mix (Abx) of ciprofloxacin (100 µg/ml) and metro-
nidazole (250 µg/ml) in their drinking water. After three weeks of Abx treatment anaerobic stool cultures were 
negative (<103 bacteria/g of feces, freshly collected in reducing buffer), and mice were placed on HFD and Abx 
was continued, and body weight and food consumed were measured each week. Control mice were started on 
HFD at the same age, but not treated with Abx. At 14 weeks after the start of HFD, mice were sacrificed, blood was 
collected for biochemical assays and liver was processed for histology and lipid assays.
Obesity in microbiota transplanted germ-free mice. One week before delivery, we colonized 
germ-free WT Swiss Webster female pregnant mice, kept under sterile conditions, with microbiota from WT 
or Nod2−/− mice maintained on HFD. Colonization was done by both gavaging with fecal microbiota and by 
co-housing. Gavaging was done into the stomach with 10 mg of fecal homogenates (containing 5 × 109 bacteria 
in 0.2 ml) prepared from freshly defecated stool samples, collected from WT or Nod2−/− mice maintained on 
HFD for 29–30 weeks, and immediately placed in reduced anaerobic medium, homogenized, and stored frozen at 
−80 °C, as previously described20, 25. At the same time, the gavaged mice were placed on HFD and also co-housing 
with Nod2−/− or WT female mice that had been maintained on HFD for 20 weeks was started and continued until 
one day after delivery. The mothers were gavaged weekly and maintained on HFD until weaning of the pups at 3 
weeks of age. Pups were gavaged at weaning and once a week thereafter, and continued on HFD. Body weight was 
measured every week and blood was collected at the time of sacrifice. We used this strategy to ensure successful 
colonization with microbiota, since we did not know whether gavaging or co-housing would be more effective 
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in transferring obesity-promoting microbiota. We colonized pregnant mice to ensure that the pups will be born 
colonized with a specific gut microbiota. The presence of microbiota at birth is essential for the normal develop-
ment of host metabolism and immune systems and alterations in the gut bacteria at birth increases susceptibility 
to diet-induced obesity57.
Histopathology of liver and adipose tissue. Liver and adipose tissue were fixed in 10% buffered forma-
lin, embedded in paraffin, sectioned, and stained with hematoxylin and eosin. Because lipid is lost with paraffin 
embedding, we also analyzed frozen liver sections stained with BODIPY 493/503 (Molecular Probes) and DAPI 
(Vector Laboratories). The liver sections were fixed in 4% paraformaldehyde/PBS for 10 min at room tempera-
ture, rinsed with PBS, and stained with 1 µg/ml of BODIPY 493/503 in PBS for 5 min at room temperature. The 
sections were rinsed with PBS and then covered with Vectashield mounting medium containing DAPI. The area 
for lipid droplets and adipocytes was measured using ImageJ and Adiposoft58, respectively.
Biochemical analyses. Mice were fasted for 5 h and blood was collected. Serum cholesterol and triglycer-
ides were quantified using fluorometric kits from BioVision Inc. Serum insulin and leptin were analyzed using 
ELISA kits from Linco Research Inc. Blood glucose was measured using the CVS/pharmacy Advanced Glucose 
Meter and test strips. Cholesterol and triglycerides were also quantified in liver homogenates (BioVision Inc).
Glucose tolerance test and estimation of insulin sensitivity. WT and Nod2−/− mice maintained on 
HFD for 29 weeks were fasted for 5 h and baseline glucose measured using blood collected from the tail vein. For 
the glucose tolerance test, mice were injected intraperitoneally with 2 g glucose/kg body weight in sterile PBS and 
blood glucose measured at 40, 80, and 120 min after injection. For the insulin sensitivity test, mice were injected 
intraperitoneally with 0.4 U/kg body weight of Humulin-R insulin (HealthWarehouse) in sterile PBS and blood 
glucose measured at 15, 30, 60, 90, and 120 min after injection.
Bomb calorimetry. To identify changes in energy extracted from the food between Nod2−/− and WT mice 
on HFD, fresh fecal samples were collected from individual mice, weighed, and frozen at −80 °C until processing. 
Samples were dried at 58 °C for 24 h, dried pellets were ground and energy content was measured using a Parr 
Oxygen Bomb Calorimeter and total caloric value computed as per the manufacturers instructions.
Lipid droplet enrichment and protein analysis. Lipid droplet enrichment. We enriched LDs using a 
modified procedure59. Freshly dissected livers were homogenized on ice with a glass Dounce homogenizer con-
taining ice-cold buffer A (20 mM tricine and 250 mM sucrose, pH 7.8) with 0.2 mM PMSF and protease inhibitor 
cocktail. The homogenate was centrifuged at 100 g for 10 min at 4 °C. The supernatant was further disrupted for 
15 min at 500 psi in a nitrogen bomb chamber and centrifuged at 3,000 g for 10 min at 4 °C to remove nuclei, cell 
debris, and unbroken cells. The post-nuclear supernatant (PNS) was transferred into a 15 ml tube and 3 ml of 
buffer B (20 mM HEPES, 100 mM KCl and 2 mM MgCl2, pH 7.4) was loaded on top and centrifuged at 2,000 g 
for 30 min at 4 °C. LDs were collected from the top band and washed several times with 200 μl buffer B and cen-
trifuged at 20,000 g for 5 min at 4 °C. The samples were mixed with chloroform/acetone (0.25:0.75, v/v), kept at 
−80 °C overnight, and proteins and lipids were separated by centrifugation at 20,000 g for 10 min at 4 °C. The 
protein pellet was air-dried, dissolved in 8 M Urea and analyzed by mass spectrometry.
Proteomic analysis by mass spectrometry. Proteins in the LD enriched fraction were identified by mass spectrom-
etry at the Laboratory for Biological Mass Spectrometry, Indiana University Bloomington. Proteins were digested 
with trypsin and purified peptides were run on an Eksigent Nano 2D HPLC coupled to a LTQ Velos Pro mass 
spectrometer (Thermo Fisher Scientific, Waltham MA). The resulting data were searched in Protein Prospector 
against the Homo sapiens or Mus musculus proteome in the SwissProt database. Spectral counting was used for 
protein quantification. Normalized data for comparison were obtained by dividing spectral count of a single 
protein by the sum of spectral counts in the same sample. The fold change was computed for Nod2−/− HFD with 
respect to WT HFD and genes with a fold change of ≥1.5 or ≤0.6 and P ≤ 0.05 were considered as significantly 
different between the 2 groups of mice.
RNA transcriptomics. For identification of genes that were differentially expressed between Nod2−/− and 
WT mice on HFD, we analyzed the total RNA population in the liver and adipose tissue by RNA sequencing. 
RNA was isolated from the liver and adipose tissue of individual WT and Nod2−/− mice maintained on HFD 
for 30 weeks using the TRIZOL method (InVitrogen), followed by purification on RNeasy spin columns using 
Qiagen RNeasy Mini Kit60. RNA sequencing and initial analysis were performed at the Center for Genomics and 
Bioinformatics, Indiana University Bloomington. 98% of all reads (~311 million reads) passed a quality filter of 
q20 requiring a minimum length of 50 bases after adapter and quality trimming, 94.7% of these mapped to the 
mouse genome assembly GRCm38.75 using tophat ver.2.0.10 and 95.5% of these mapped uniquely. The reads 
were annotated using the software DAVID61 and differential expression with statistical analysis was calculated 
using the software DESeq262. The fold change was computed for Nod2−/− HFD with respect to WT HFD and 
genes that had a fold change of ≥2 or ≤0.5 and P ≤ 0.05 and with a 5% FDR were considered as significantly 
different between the 2 groups.
Isolation of stromal/vascular cells from adipose tissue and flow cytometry. Stromal/vascular 
fraction from adipose tissue, which contains immune cells, was isolated using a modified procedure63. Visceral 
adipose tissue was isolated, weighed, and digested with 1 mg/ml collagenase D and 0.15 μg/ml DNAse I in RPMI-
5FCS (RPMI-1640 supplemented with 5% FCS) for 40 min in a shaking 37 °C water bath and samples were cen-
trifuged at 1,000 rpm for 10 min at room temperature; at this speed adipocytes stay on the top and the stromal/
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vascular (SV) cells form a pellet. The supernatant with the adipocytes was carefully removed and discarded and 
the pellet was resuspended in RPMI-5FCS and filtered through a 100 μm filter to remove any remaining adi-
pocytes. SV cells were stained with CD45-Vioblue and F4/80-APC (Biolegend) for 20 min, analyzed by flow 
cytometry using MACSQuant (Miltenyi) cytometer and F4/80 positive cells were measured within the CD45 gate.
Gut microbiome analysis. Stool collection and DNA extraction. We collected freshly defecated stools from 
individual female WT and Nod2−/− mice (200 mg/mouse, 6 mice/strain) maintained for 28–30 weeks on HFD or 
LFD and isolated DNA using the MoBio Fecal DNA isolation kit25. For each genotype, mice originated from three 
different litters from different parents and 2 mice per litter), weaned into separate cages, and all cages were kept in 
the same room in our animal facility. This strategy allows stabilization of microbiota and minimizes the variability 
observed between different litters due to different parents and different cages and rooms20, 25, 60.
Pyrosequencing of 16S rRNA genes and microbiome analysis. Genetic phylotyping (community profiling) 
using pyrosequencing of the variable regions of bacterial 16 S ribosomal RNA (rRNA) genes with 16 S univer-
sal Eubacterial primers 530 F (5′-GTG CCA GCMGCN GCG G) and 1100 R (5′-GGG TTN CGN TCG TTG) 
was performed using Roche 454 technology and bTEFAP® pipeline at MR DNA Molecular Research LP25, 64. A 
single-step 30 cycle PCR using HotStarTaq Plus Master Mix Kit (Qiagen) was used under the following condi-
tions: 94 °C for 3 min, followed by 28 cycles of 94 °C for 30 sec, 53 °C for 40 sec, and 72 °C for 1 min, and elonga-
tion step at 72 °C for 5 min. Following PCR, all amplicon products from different samples were mixed in equal 
concentrations and purified using Agencourt Ampure beads (Agencourt Bioscience Corporation). Samples 
were sequenced using Roche 454 FLX titanium instrument and reagents by following manufacturer’s guidelines. 
Sequencing data were processed using MR DNA Molecular Research LP analysis pipeline (www.mrdnalab.com), 
including depletion of barcodes and primers, removal of short sequences (<200 bp), sequences with ambigu-
ous base calls, and sequences with homopolymer runs exceeding 6 bp, de-noising, and removal of chimeras65. 
Operational taxonomic units (OTUs) were then defined after removal of singleton sequences and clustering, 
and taxonomically classified using BLASTn against a curated GreenGenes database and assigned to species at 
>97% identity to the reference sequence (<3% divergence), to genus at 95%–97% identity, family at 90%–95% 
identity, order at 85%–90% identity, class at 80%-85% identity, phylum at 77%-80% identity, and unclassified at 
<77% identity66. We compared the sequences and analyzed the changes in bacterial ecology using Quantitative 
Insights Into Microbial Ecology (QIIME; http://qiime.sourceforge.net), Bayesian, PyNAST, and UniFrac67–69. The 
Shannon diversity index H = –Σpi ln(pi) and Shannon equitability index EH = H/ln(S), where pi is the proportion 
of the ith taxonomic unit (OTU or species) and S is the total number of taxonomic units, were calculated using 
Microsoft Excel. The average total number of reads per mouse was 6978, with no significant differences between 
the numbers of reads/mouse between WT and Nod2−/− and HFD and LFD mice, and detected bacteria with a 
frequency of >0.001%.
Statistical analysis. The significance of differences between the numbers of recovered bacterial species and 
OTUs was determined by the z-test using Microsoft Excel. The significance of differences between all other quan-
titative results presented as means ± SEM were determined by the Student’s t-test using Microsoft Excel or by 
ANOVA using Prism. The N and P values are indicated in the Figures and Tables; P ≤ 0.05 was considered signif-
icant. The heatmaps were generated using Java TreeView and represent mean fold changes in Nod2−/− HFD mice 
relative to WT HFD mice, after converting <1 ratios to negative fold difference using the formula: (−1)/ ratio.
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